17:44:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-27 X-dag ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-06-24 Kvartalsrapport 2024-Q1
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 X-dag ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 X-dag ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 X-dag ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2024-04-17 07:55:00
Presentation of "The New SoftOx" at  

https://investorweb.no/ir-channel/SOFTX/event - Thursday the 18th of April 1 pm.


The presentation will be recorded and made available afterwards.

SoftOx Solutions AS has been through a rough period. Over the last one and a
half years the Company has been forced to make drastic changes. A new strategy
has been developed. The term "New SoftOx" is internally used to mark this shift
in strategy.

An important milestone in this work was to refinance the Company. Nearly all
debt is now converted to shareholder capital. The former shareholders are now
given the right to participate in this refinancing on similar terms as the debt
holders.

The "new SoftOx" will aim to disrupt today's infection treatment in respiratory
and chronic wounds, building on the unique properties of the SoftOx technology.
Clinical experiments and product development will be conducted in close
cooperation with our partners under supervision of project leaders from SoftOx.

With the new strategy the Company has significantly reduced the running costs.
The manning is reduced to a slim organization that will manage outsourced
research and development.

The Board recommends that SoftOx Solutions AS will be split into two entities.
This sets the condition to be focused on two different segments.

Today's presentation will mainly focus on presenting the business area SoftOx
Inhalation AS. SoftOx Solutions AS will be renamed to SoftOx Inhalation AS, and
will remain being listed on Oslo Euronext Growth. The company will develop a
solution to treat Ventilator Associated Pneumonia (VAP) in patients admitted to
intensive care. VAP is a frequent and lethal threat to patients on ventilators.
In addition, SoftOx Inhalation will continue the important work with our
partners in the European Defence Fund (EDF) to develop a countermeasure to
protect soldiers against biological warfare agents spread through the
respiratory system. The defense project is fully financed by EDF, all commercial
rights will be the property of SoftOx. Both VAP and EDF projects will outsource
the research and development to the University of Copenhagen.

Welcome.